Toggle Main Menu Toggle Search

Open Access padlockePrints

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

Lookup NU author(s): Dr Lei Huang, Professor Andrew Mellor

Downloads


Licence

This is the authors' accepted manuscript of an article that has been published in its final definitive form by Elsevier Ireland Ltd., 2019.

For re-use rights please refer to the publisher's terms and conditions.


Abstract

Cancer immunotherapy is a new and promising option for cancer treatment. Unlike traditional chemo- and radiotherapy, immunotherapy actives host immune system to attack malignancies,and this potentially offers long-term protection from recurrence with less toxicity in comparison to conventional chemo- and radiation therapy. In adoptive CD8+ T cell therapy (ACT), large numbers of tumor-specific T cells are sourced from patients and expanded in vitro and infused back to patients. T cells can be expanded from naturally-induced tumor-specific CD8+ T cells isolated from tumor infiltrating lymphocytes (TIL) or genetically-modified autologous circulating CD8+ T cells. The engineered T cells expressed tumor-specific antigen receptors including chimeric antigen receptors (CARs) and T cell receptors (TCRs), prepared from cultured B and T cell clones, respectively. The most successful ACT, anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy directed against B cell lymphoma, is already approved for use based on evidence of efficacy. Efficacy of solid tumors is not yet forthcoming. This review summarizes current technology developments using ACT in clinical trials. In this review, differences between various ACT approaches are discussed. Furthermore, resistance factors in the tumor microenvironment are also considered, as are immune related adverse effects, critical clinic monitoring parameters and potential mitigation approaches.


Publication metadata

Author(s): Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, Mellor A, Wang W, Wu S

Publication type: Article

Publication status: Published

Journal: Cancer Letter

Year: 2019

Volume: 462

Pages: 23-32

Print publication date: 10/10/2019

Online publication date: 26/07/2019

Acceptance date: 23/07/2019

Date deposited: 31/07/2019

ISSN (electronic): 0304-3835

Publisher: Elsevier Ireland Ltd.

URL: https://doi.org/10.1016/j.canlet.2019.07.017

DOI: 10.1016/j.canlet.2019.07.017

PubMed id: 31356845


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share